Area of research
Oncology · Surgery
Research interest
Research focused on Denosumab and Zoledronic acid, with related work in Malignancy, Breast cancer, Brief Pain Inventory. Notable publications include 'Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials', 'Denosumab for Treatment of Hypercalcemia of Malignancy', and 'Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer'.
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
Denosumab for Treatment of Hypercalcemia of Malignancy
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).
Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Pain outcomes in patients with advanced breast cancer and bone metastases